Correction: Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)

Affiliations

• ¹ Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan. [email protected].
• ² Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
• ³ Cancer Center, Gifu University Hospital, Gifu, Japan.
• ⁴ Division of Digestive Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
• ⁵ Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
• ⁶ Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
• ⁷ Department of Genetic Oncology, Osaka International Cancer Institute, Osaka, Japan.
• ⁸ Division of Gastroenterology, Chiba Cancer Center, Chiba, Japan.
• ⁹ Department of Surgery, Kindai University Faculty of Medicine, Osakasayama, Japan.
• ¹⁰ Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
• ¹¹ Oncology Medical Science Department I, Daiichi Sankyo Co. Ltd., Tokyo, Japan.
• ¹² Data Intelligence Department, Daiichi Sankyo Co. Ltd., Tokyo, Japan.